HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Benner, J. S. Articles by Williams, S. A. Search for Related Content PubMed PubMed Citation Articles by Benner, J. S. Articles by Williams, S. A.

JOSHUA S. BENNER, PHARM.D., SC.D., is Principal, ValueMedics Research, LLC, Falls Church, VA. MICHAEL F. POLLACK, M.S., is Senior Research Analyst, Health Core, Inc. (HCI), Newark, DE; at the time of this study he was employed by ValueMedics Research. TIMOTHY W. SMITH, B.S., is Director of Informatics, ValueMedics Research. MICHAEL F. BULLANO, PHARM.D., is Director of Analytics and VINCENT J. WILLEY, PHARM.D., is Vice President of Research, HCI. SETAREH A. WILLIAMS, PH.D., is Director, Health Economics, Astra-Zeneca LP, Wilmington, DE.

Address correspondence to Dr. Benner at ValueMedics Research, LLC, 300 N. Washington Street, Suite 303, Falls Church, VA 22046 (josh.benner{at}valuemedics.com).

Purpose. The relationship between low-density lipoprotein (LDL) cholesterol reduction in the first 3 months of statin therapy and medication adherence during a 33-month follow-up period was studied. Methods. A retrospective cohort study was conducted among enrollees in a Southeastern managed care plan who started therapy with atorvastatin, fluvastatin, lovastatin, pravastatin, or simvastatin between October 1999 and August 2001, were enrolled for 12 months before and 6 months after treatment initiation, and had at least one LDL cholesterol measurement in the year before and 4–12 weeks after the start of therapy. Patients were followed up via electronic pharmacy and medical records for up to 33 more months. The follow-up period was divided into 3-month intervals; patients were considered adherent if statin therapy was available 80% of the time. A generalized linear model for repeated measures quantified the association between change in LDL cholesterol at 4–12 weeks and medication adherence in subsequent intervals, adjusting for demographic, clinical, and health-service-use variables. Results. The final sample consisted of 9510 patients. Medication adherence decreased significantly over time: 59%, 40%, 34%, and 21% of patients were adherent at 3, 6, 12, and 36 months, respectively. Mean ± S.D. LDL cholesterol reduction at 12 weeks was 28.9% ± 19.9%. The relative LDL cholesterol reduction at 12 weeks was significantly and independently associated with subsequent medication adherence: Compared with subjects in the first quartile of LDL cholesterol reduction, those in quartiles 2, 3, and 4 were more likely to be adherent in any subsequent interval (adjusted odds ratio [95% confidence interval], 1.26 [1.12–1.42], 1.25 [1.11–1.40], and 1.15 [1.02–1.29], respectively). Other independent predictors of adherence in months 4–36 included adherence during the initial three months of therapy, age, and recent history of coronary revascularization. Conclusion. Greater reduction in LDL cholesterol levels during the first three months of statin therapy was associated with greater adherence to lipid-lowering drug therapy. Index terms: Age; Antilipemic agents; Atorvastatin; Compliance; Fluvastatin; Hypercholesterolemia; Lovastatin; Patients; Pravastatin; Simvastatin